ERBB2 and breast carcinoma: However, our lab has demonstrated that PARP-1 inhibition also kills HER2+ breast cancer cells despite proficient HR repair, indicating PARP-1 may be an effective treatment for non-familial, sporadic cancers as well as familial cancers [61].